Danni Li

Parkville, VIC 3010, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Proteomic Insights into Intrauterine Growth Restriction and Its Role in Asthma Pathogenesis.

Proteomic Insights into Intrauterine Growth Restriction and Its Role in Asthma Pathogenesis.

Journal: Journal of proteome research

Published: June 12, 2026

Microbial modulation of CFTR modulator exposure: In vitro interactions between elexacaftor-tezacaftor-ivacaftor and pulmonary and gut bacteria from people with cystic fibrosis.

Microbial modulation of CFTR modulator exposure: In vitro interactions between elexacaftor-tezacaftor-ivacaftor and pulmonary and gut bacteria from people with cystic fibrosis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: June 03, 2026

Repurposing ivacaftor to attenuate LPS-induced acute lung injury: evidence from a non-cystic fibrosis model.

Repurposing ivacaftor to attenuate LPS-induced acute lung injury: evidence from a non-cystic fibrosis model.

Journal: Frontiers in pharmacology

Published: January 14, 2026

Hyperfiltration and Elevated Fractional Excretion of Magnesium in Children with Cystic Fibrosis.

Hyperfiltration and Elevated Fractional Excretion of Magnesium in Children with Cystic Fibrosis.

Journal: ACS pharmacology & translational science

Published: May 04, 2025

Lens-related ocular changes in fetal rats following in-utero exposure to elexacaftor-tezacaftor-ivacaftor.

Lens-related ocular changes in fetal rats following in-utero exposure to elexacaftor-tezacaftor-ivacaftor.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: August 20, 2024

The role of CFTR in the eye, and the effect of early highly effective modulator treatment for cystic fibrosis on eye health.

The role of CFTR in the eye, and the effect of early highly effective modulator treatment for cystic fibrosis on eye health.

Journal: Progress in retinal and eye research

Published: February 27, 2024

Recommended Tool Compounds for Modifying the Cystic Fibrosis Transmembrane Conductance Regulator Channel Variants.

Recommended Tool Compounds for Modifying the Cystic Fibrosis Transmembrane Conductance Regulator Channel Variants.

Journal: ACS pharmacology & translational science

Published: December 14, 2023

Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.

Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 20, 2023

Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy.

Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy.

Journal: British journal of pharmacology

Published: October 24, 2023

Ocular development after highly effective modulator treatment early in life.

Ocular development after highly effective modulator treatment early in life.

Journal: Frontiers in pharmacology

Published: July 22, 2023

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis.

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis.

Journal: Pharmaceutics

Published: March 30, 2023

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis.

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis.

Journal: Antibiotics (Basel, Switzerland)

Published: February 10, 2023

Showing 1-12 of 13

Last Updated: 09/26/2026